Centrosome-related Service for Breast Cancers

Centrosome abnormalities (CAs) is an established hallmark of cancer, which is potential prognosticators in various cancers. Abnormality in centrosome size, shape and quantity are included in CAs, which are highly correlated with breast cancers. CD BioSciences provides CAs detection service in breaster cancer with our advanced technology and experienced experts for meeting our global customer's demands in centrosome research and the therapeutic development of centrosome-related disease.

Relevance between Centrosome & Breast Cancers (BC)

Breast cancer are classified by expression of estrogen receptors (ER) or progesterone receptors (PR) and amplification of epidermal growth factor receptor 2 (HER2). Tumors lacking these receptors are called triple negative breast cancer (TNBC) and majority of them are basal subtype. What's more, all breast cancer subtypes exhibit some degree of chromosome instability (CIN). Centrosome plays key role in regulating CIN, due to its core function in mitosis. The centrosome abnormality (CA) is highly correlated with the malignant tumor through several processes, excessive recruitment of PCM, such as hormone signaling perturbation, mutation-induced dysfunction of centrosome proteins, abnormal kinase regulation, centrosome gene dysregulation, cytokinesis failure and cell–cell fusion.

How CAs fuel tumor evolution and generate (Ogden A, et al., 2017)

The CAs are frequently observed in breast tumor, especially centrosome amplification, which refers to an abnormal increase in the number of centrosomes in the cell, and centrosome structural amplification, which exhibit an increased volume of its size. And the CAs are highly involved in chromosome instability, invasive behavior, distant metastases, and cytoarchitecture disruption. Centrosome offers a potential prognostic tool and therapeutic target in breast cancer.
Generally, the technology of CAs detection is the digital analysis of fluorescence confocal microscopy images to yield an assessed score, which tells the relevance between CAs and degree of cancer. Fluorochrome-labeled antibodies are used to detect centrosome proteins, such as γ-tubulin, CEP proteins and PCM proteins. With developed algorithm, the volume and the quantity are assessed considering the stage of cancer, age of patient, race of patient, the extent of treatment and many other factors.

Representative images of breast tissue (Mittal K, et al., 2021)

Our Services

The centrosome abnormalities have been used for diagnose the development stage of breast cancer. And due to the strong relevance between centrosome abnormalities and breast cancer, launching the studies of centrosomal genes and biological processes centrosome involved in seem to be of great value. For assisting out global customers making better progress in the fields of diagnosis and therapeutic development of cancer, CD BioSciences offers centrosome-based breast cancer detection service. The workflow is as follows.

Why Choose Us

Professional Team

Comprehensive Platform

High Efficiency

One-stop Service

With skilled and experienced genomics and cytology experts, state-of-the-art equipment and advanced technology, CD BioSciences offers customer all over the word services related to fields of centrosomal research. Our one-stop service program is your best assistant to accelerate you process of centrosomal research. Please feel free to contact us and get started with our high-quality services.

References

1. Ogden A, et al., Centrosome amplification: a suspect in breast cancer and racial disparities. Endocr Relat Cancer. 2017 Sep;24(9):T47-T64.
2. Mittal K, et al., Centrosome amplification: a quantifiable cancer cell trait with prognostic value in solid malignancies. Cancer Metastasis Rev. 2021 Mar;40(1):319-339.

Our services are for research use only and not for any clinical use.